Colorectal cancer (CRC) can be cured if found early, but current screening tools like endoscopy and the CEA blood test often miss early-stage disease. Researchers have developed a new blood test called the SERS eCRC Metabolites Model (SCMM), which combines nanotechnology and artificial intelligence to detect tiny metabolic changes linked to early cancer.
The team created a special 3D surface coated with silver nanoparticles that greatly amplifies weak chemical signals in the blood. This design produces powerful “hot spots” that boost signals up to 180 billion times, allowing detection of extremely small amounts of cancer-related molecules. Using advanced mass spectrometry, researchers identified three key metabolites—corticosterone, homogentisic acid, and 5,6-dimethyl-4-oxo-4H-pyran-2-carboxylic acid—as early biomarkers. A deep learning system called a Convolutional Neural Network (CNN) then analyzed the complex signal patterns to distinguish cancer patients from healthy individuals.In a study of 139 participants, the model achieved 94.4% overall accuracy and 100% specificity. It correctly identified 92.7% of patients who were negative on the traditional CEA test and was especially effective in detecting small tumors and cancers in people under 50. Researchers now plan to adapt the technology into por